Abstract

Daily Lactose Supplementation in Lactase Non-Persistent Individuals Induces Colonic Adaptation and Reduces Intolerance Symptoms †

Ellen Looijesteijn 1,*, Lonneke JanssenDuijghuijsen 2, Maartje van den Belt 2, Beatrix Gerhard 3, Renata Ariens 2,©, Reina Tjoelker 1 and Jan Geurts 1

1 FrieslandCampina, 3818 LE Amersfoort, The Netherlands; reina.tjoelker@frieslandcampina.com (R.T.);
jan.geurts@frieslandcampina.com (J.G.)
2 Wageningen Food and Biobased Research, Wageningen University & Research, 6708 WG Wageningen, The Netherlands; lonneke.janssenduijghuijsen@wur.nl (L.J.);
maartje.vandenbelt@wur.nl (M.v.d.B.); renata.ariens@wur.nl (R.A.)
3 Biomax Labvantage, 85152 Planegg, Germany; beatrix.gerhard@labvantage-biomax.com
* Correspondence: ellen.looijesteijn@frieslandcampina.com

Abstract: Background and objectives: Globally, about 70% of the adult population is lactase non-persistent (LNP), lacking the enzyme required for lactose digestion. The main consequence of intolerance is withholding nutrient-rich dairy foods, while the literature shows that many LNPers are able to consume ≤12 g of lactose, comparable to 250 mL of milk, without experiencing gastrointestinal discomfort. Repetitive consumption of lactose may improve intolerance symptoms even further via colonic adaptation. This study aimed to assess the effects of daily consumption of incremental lactose doses on microbiota composition and function, and intolerance symptoms. Methods: Twenty-five healthy adults of Asian origin (age 22–44 yrs, BMI 19–28 kg/m²), carrying the LNP genotype and avoiding lactose in their habitual diet, were included in this 12-week single-blinded intervention trial. Participants consumed lactose twice daily, with doses being gradually increased from 3 to 6 g, to finally 12 g twice daily, each dose being provided for 4 consecutive weeks. Before and after the 12-week intervention, participants underwent a 25 g lactose challenge hydrogen breath test (HBT) and handed in stool samples. Daily gastrointestinal symptoms and acute intolerance symptoms during the HBT were recorded. Results: There was a significant increase in Bifidobacterium after 12 weeks of lactose consumption (p = 0.009), accompanied by a two-fold increase (p < 0.001) in fecal β-galactosidase activity. There was a 1.5-fold decrease (AUC; p = 0.01) in expired hydrogen during the second compared to the baseline HBT. There was a non-significant decrease in total symptom score (p = 0.09) during this second HBT, which was already relatively low during the baseline HBT. Daily consumption of lactose was generally well tolerated, with mild to no gastrointestinal complaints reported during the intervention. Discussion: Repetitive consumption of incremental doses of lactose increases lactose tolerance in LNP individuals via colonic adaptation, most likely through increasing the relative abundance of lactose-fermenting Bifidobacterium. Repetitive lactose consumption is well tolerated and able to reduce expired hydrogen during a 25 g lactose HBT. Here, we show that regular and incremental exposure to lactose in LNP individuals leads to colonic adaptation without any increase in gastrointestinal symptoms. This lifts the necessity to remove dairy foods completely from the diet.

Keywords: lactose intolerance; Bifidobacterium; β-galactosidase activity; colonic adaptation; hydrogen breath test
Author Contributions: L.J., E.L., R.T. and J.G. designed research; L.J., M.v.d.B. and R.A. conducted research; L.J., M.v.d.B., R.A. and B.G. analyzed data and/or performed statistical analysis; L.J. and E.L. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Dutch ministry of Economic affairs via a Public Private Partnership grant from the Top consortium for Knowledge and Innovation Agri & Food, project LWV20.043 “Lactastic”. The funding agency had no role in the collection, analyses, and interpretation of data; or in the preparation, review, or approval of the manuscript. The following companies contributed to the funding of this project: FrieslandCampina (Amersfoort, the Netherlands) and Biomax LabVantage (Planegg, Germany).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Medical Ethical Committee of Utrecht (protocol code NL74025.081.20, approved 25 May 2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data described in the manuscript and analytic code will not be made available because this was not stated in the ethics application.

Conflicts of Interest: E.L., R.T. and J.G. were employees of FrieslandCampina at the time of conceptual development and submission of the manuscript. L.J. was employee of FrieslandCampina at the time of conceptual development but switched employment prior to study execution.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.